Should I buy Tenet Health (THC) stock or is it too late?

Tenet Health · Health Care · price $267

⭐ What the most reliable analysts say · those who beat their sector, targets replayed on real prices

⭐ The most reliable of them, either direction: Guggenheim — 77% of its targets hit on this sector (53 calls tested). It aims for $283 (+6.0 %), call made on July 29, 2026, maturing on July 29, 2027 (77 d ago).

The 8 reliable analysts $283+6.0 %

The 5 other firms $265-0.7 %

How to read it: the 8 reliable firms are not filtered by optimism — 7 aim above the price, 1 below, hence their $283 median. “The 5 others” are the firms that don't pass our reliability filter on this sector.

Firm-by-firm track record on Tenet Health

Here the hit rate is measured <b>on this stock specifically</b> (matured targets replayed against real prices, minimum 5 calls tested) — the green block above measures reliability <b>across the whole sector</b>, which is the criterion behind JPI selections. “Aims for” = the firm's most recent target on this stock; “—” means it hasn't published one recently.

Firm	% right	Gain vs sector	Calls	Aims for
UBS	88 %	+74.6 %	16	$308 +15%
B of A Securities	100 %	+47.1 %	5	$225 -16%
RBC Capital	82 %	+46.9 %	11	$283 +6%
Jefferies	67 %	+45.7 %	9	$265 -1%
Wells Fargo	82 %	+41.2 %	17	$281 +5%
Cantor Fitzgerald	100 %	+37.5 %	17	$245 -8%
Truist Securities	93 %	+36.9 %	15	$290 +9%
Mizuho	72 %	+30.9 %	18	$265 -1%

In short — Should you invest in Tenet Health? Is it too late, still worth it? Analysts are overwhelmingly positive (85% buy, median target $280, i.e. +5%), and the most reliable on THC targets even higher. But it pays virtually no dividend. We give you both sides, with the numbers — not advice.

✅ Reasons to believe

85% of analysts rate it a buy (Buy consensus, 13 ratings) — a sign of market conviction.
The most reliable firm on THC, Guggenheim (100% hit rate, 2 scored calls), targets $283 (call made on July 28, 2026, maturing on July 28, 2027) (+6%) in its most recent call, and $238 (call made on October 29, 2025, maturing on October 29, 2026) (-11%) in the one coming due soonest.

⚠️ Reasons to hesitate

The consensus is not unanimous: of 13 ratings, 2 are neutral.
Limited upside: the median target is only +5% from the current price.
A 12-month target is not a guaranteed path: the price can fall in the meantime.
No dividend: your return depends only on price appreciation.

The analyst consensus on THC

Median target $280 (+5%) · 13 ratings · Buy consensus

Strong Buy00%

Buy1185%

Hold215%

Sell00%

Strong Sell00%

⚠️ Information, not investment advice. Past performance does not guarantee future results. Analyst targets on a ~12-month horizon.

Frequently asked questions

Should you invest in Tenet Health now?

We won't decide for you. The facts: 85% of analysts rate it a buy, median target $280 (+5%), and Guggenheim (most reliable on THC, 100%) targets $283. Weigh that against valuation. This is not personalized advice.

Is it too late to invest in Tenet Health?

Not according to analysts: the median target ($280) is still +5% above the current price ($267) (most reliable on THC: Guggenheim, 100%). The real question isn't "too late" but the price-to-value gap and risk. Not advice.

Is Tenet Health still worth investing in?

It depends on the gap between the price ($267) and its estimated value: analysts target $280 on median (+5%), with 85% buys (most reliable on THC: Guggenheim, 100%). Cross-check with their real reliability on THC and the cautions above. Information, not advice.

What's the main risk in buying THC?

The consensus is not unanimous: of 13 ratings, 2 are neutral.

→ Go deeper: the full Tenet Health profile (consensus, analyst reliability, price target, performance).